Shionogi Wins U.S. Contract to Advance Fetroja Antibiotic

Shionogi & Co., Ltd. has secured a major U.S. government contract to expand the development and supply of its antibiotic Fetroja, reinforcing efforts to combat drug-resistant infections and strengthen national health security preparedness.

The contract, awarded to its U.S. subsidiary Shionogi Inc. through Biomedical Advanced Research and Development Authority under Project BioShield, carries an initial funding of $119 million. With additional multi-year options, the total value could reach up to $482 million.

Fetroja (cefiderocol), a novel siderophore cephalosporin antibiotic, is designed to treat serious Gram-negative bacterial infections, including those resistant to multiple drugs. The agreement aims to enhance the U.S. government’s ability to respond to high-priority biological threats while also strengthening domestic manufacturing and supply chain readiness.

Under the terms of the contract, Shionogi will establish a U.S.-based manufacturing site for Fetroja, ensuring a more reliable domestic supply. The funding will also support procurement of the drug and advance its development for use against dangerous pathogens such as Burkholderia pseudomallei, which causes melioidosis, and Yersinia pestis, the bacterium responsible for plague. Both are considered significant biothreat agents.

Additionally, the company plans to expand the use of Fetroja in pediatric patients suffering from hospital-acquired and ventilator-associated bacterial pneumonia through a supplemental New Drug Application to the U.S. Food and Drug Administration.

John Keller, senior vice president of research and development at Shionogi, emphasized the company’s long-standing commitment to antibiotic innovation, noting that Fetroja represents a key example of its in-house scientific advancements. He added that the contract reflects continued collaboration with global health authorities to address urgent medical needs.

Nathan McCutcheon, President and CEO of Shionogi Inc., highlighted the company’s broader efforts to tackle antimicrobial resistance, including ongoing investments in research and acquisitions aimed at strengthening its antibiotic pipeline. He stated that the new agreement would accelerate the company’s expansion in the United States.

Fetroja is already approved in the U.S. for treating hospital-acquired bacterial pneumonia, ventilator-associated pneumonia, and complicated urinary tract infections caused by susceptible Gram-negative organisms. It is also marketed in Japan and Europe under different brand names.

The award underscores growing global concern over antimicrobial resistance and the need for advanced treatments to address both everyday infections and potential biothreat scenarios.